The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Jean-Jacques Kiladjian
Aaron GerdsVideo series
On June 28, 2023, Scientific Education Support hosted a clinical trial club entitled “NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of advanced myelofibrosis.”
The webinar reviewed the phase II NCT03194542 trial investigating luspatercept, an activin receptor ligand trap, for the treatment of anemic myelofibrosis. The event was chaired by Jean-Jacques Kiladjian, Université de Paris - Hôpital Saint-Louis, Paris, FR, who was joined by trial investigator, Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US.
Kiladjian began by outlining the mechanism of action of luspatercept. He highlighted the importance of erythropoiesis, the role of TGF-β superfamily signaling, and how luspatercept reduces SMAD2/3 signaling.
More from this series:
